C

Corvus Pharmaceuticals
D

CRVS

4.68000
USD
-0.33
(-6.59%)
Market Open
Volume
22,365
EPS
-1
Div Yield
-
P/E
-5
Market Cap
302,009,080
OverviewSignalsIdeasNews
Related Instruments
    A
    ABUS
    0.01500
    (0.47%)
    3.21500 USD
    A
    ARWR
    0.160
    (0.82%)
    19.610 USD
    C
    CRSP
    -0.450
    (-1.11%)
    40.270 USD
    E
    EDIT
    -0.06000
    (-4.55%)
    1.26000 USD
    F
    FIXX
    0
    (0%)
    0.000000 USD
    N
    NVTA
    0
    (0%)
    0.000000 USD
    REGN
    REGN
    11.07
    (1.58%)
    713.67 USD
    R
    RGNX
    -0.30000
    (-3.93%)
    7.33000 USD
    S
    SRPT
    0.010
    (0.01%)
    118.980 USD
    V
    VYGR
    -0.06000
    (-1.04%)
    5.70000 USD
    More
News

Title: Corvus Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).